TY - JOUR
T1 - Salivary Gland Cancers of the Nasopharynx
T2 - A Population-Based Analysis of 383 Cases
AU - Booth, J. Renee
AU - Unsal, Aykut A
AU - Tadros, Sandra
AU - Byrd, James Kenneth
AU - Kountakis, Stilianos E
N1 - Publisher Copyright:
© American Academy of Otolaryngology–Head and Neck Surgery Foundation 2019.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objectives/Hypothesis: Salivary gland nasopharynx cancers (SGNPCs) are rare malignancies with few cases discussed in the literature. This study represents the largest cohort of SGNPC to date. Study Design: Retrospective population-based analysis. Methods: The Surveillance, Epidemiology, and End Results registry from 1973 to 2015 was utilized to extract 383 cases of SGNPC. Data were analyzed for demographic characteristics, incidence, clinicopathologic traits, and outcome prognosticators. Results: White female patients aged >40 years were most commonly affected. The incidence was measured as 0.019 per 100,000 people. The majority of tumors presented at advanced stages (stage III/IV, 60.8%). Adenoid cystic carcinoma, adenocarcinoma, and mucoepidermoid carcinoma were the most commonly encountered histologies (43.1%, 31.6%, 13.3%, respectively). Cervical node involvement and distant metastasis were measured at 23% and 11.9%, respectively. Mucoepidermoid carcinomas presented with the best disease-specific survival at 5 and 10 years. Asian ethnicity, age <80 years, and earlier American Joint Committee on Cancer stages were positive prognostic factors. The inclusion of surgical therapy improved 5-year outcomes among the most common histologies, except for mucoepidermoid carcinoma. Conclusions: Salivary gland nasopharyngeal cancer represents a group of rare histologies with similar outcomes as squamous cell carcinomas. However, prognosis is primarily dependent on histologic subtype, race, age, and American Joint Committee on Cancer stage.
AB - Objectives/Hypothesis: Salivary gland nasopharynx cancers (SGNPCs) are rare malignancies with few cases discussed in the literature. This study represents the largest cohort of SGNPC to date. Study Design: Retrospective population-based analysis. Methods: The Surveillance, Epidemiology, and End Results registry from 1973 to 2015 was utilized to extract 383 cases of SGNPC. Data were analyzed for demographic characteristics, incidence, clinicopathologic traits, and outcome prognosticators. Results: White female patients aged >40 years were most commonly affected. The incidence was measured as 0.019 per 100,000 people. The majority of tumors presented at advanced stages (stage III/IV, 60.8%). Adenoid cystic carcinoma, adenocarcinoma, and mucoepidermoid carcinoma were the most commonly encountered histologies (43.1%, 31.6%, 13.3%, respectively). Cervical node involvement and distant metastasis were measured at 23% and 11.9%, respectively. Mucoepidermoid carcinomas presented with the best disease-specific survival at 5 and 10 years. Asian ethnicity, age <80 years, and earlier American Joint Committee on Cancer stages were positive prognostic factors. The inclusion of surgical therapy improved 5-year outcomes among the most common histologies, except for mucoepidermoid carcinoma. Conclusions: Salivary gland nasopharyngeal cancer represents a group of rare histologies with similar outcomes as squamous cell carcinomas. However, prognosis is primarily dependent on histologic subtype, race, age, and American Joint Committee on Cancer stage.
KW - SEER
KW - Surveillance Epidemiology and End Results
KW - adenocarcinoma
KW - adenoid cystic carcinoma
KW - disease-specific survival
KW - incidence
KW - mucoepidermoid carcinoma
KW - nasopharyngeal cancer
KW - papillary adenocarcinoma
KW - population-based
KW - salivary gland tumors
KW - salivary gland type nasopharyngeal cancer
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85067844634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067844634&partnerID=8YFLogxK
U2 - 10.1177/0194599819849923
DO - 10.1177/0194599819849923
M3 - Article
C2 - 31084265
AN - SCOPUS:85067844634
SN - 0194-5998
VL - 161
SP - 442
EP - 449
JO - Otolaryngology - Head and Neck Surgery (United States)
JF - Otolaryngology - Head and Neck Surgery (United States)
IS - 3
ER -